Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bio-Rad Laboratories, Inc. Class A Common Stock (NY: BIO )

249.75 +0.90 (+0.36%)
Streaming Delayed Price Updated: 3:56 PM EDT, Apr 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bio-Rad Laboratories, Inc. Class A Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Bio-Rad to Present Company Overview at J.P. Morgan 41st Annual Healthcare Conference
From Bio-Rad Laboratories, Inc.
Via Business Wire
Bio Rad Has Almost 40% Upside On Revenue Acceleration And Margin Improvement, Analyst Says
Via Benzinga
Bio-Rad To Participate in Fireside Chat During Credit Suisse’s 31st Annual Healthcare Conference
From Bio-Rad Laboratories, Inc.
Via Business Wire
Bio-Rad Reports Third-Quarter 2022 Financial Results
From Bio-Rad Laboratories, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Friday
  During Friday, 125 stocks hit new 52-week lows. 
Via Benzinga
Bio-Rad to Report Third Quarter 2022 Financial Results on Thursday, October 27, 2022
From Bio-Rad Laboratories, Inc.
Via Business Wire
Why Bio-Rad Laboratories' Rumored $10 Billion Qiagen Buyout Looks Unlikely
One analyst doubts any deal could come to fruition. If it did, it would make sense. 
Via Investor's Business Daily
Twitter May Drop Clickable Hashtags, AstraZeneca's Nasal COVID-19 Vaccine Fails Trial, Coinbase Gets Singapore Nod: Top Stories Tuesday, Oct. 11
Reuters US-China Chip War: KLA Relaxes Chip Supply To China 
Via Benzinga
Bio-Rad Laboratories, Qiagen Mull Merger Of Equals
Bio-Rad Laboratories Inc (NYSE: BIO) is reportedly in talks to merge with Qiagen NV (NYSE: QGEN), but any agreement isn't likely for another few weeks or more, or it may not happen at all. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 25, 2022
Upgrades 
Via Benzinga
Bio-Rad Acquires Curiosity Diagnostics
From Bio-Rad Laboratories, Inc.
Via Business Wire
Bio-Rad Laboratories: Q2 Earnings Insights
Bio-Rad Laboratories (NYSE:BIO) reported its Q2 earnings results on Thursday, July 28, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Bio-Rad Reports Second-Quarter 2022 Financial Results
From Bio-Rad Laboratories, Inc.
Via Business Wire
Tesla, Danaher And Some Other Big Gainers From Yesterday
U.S. stocks closed higher on Thursday, with the Nasdaq Composite jumping around 1.4%. Here is the list of some big stocks recording gains in the previous session. 
Via Benzinga
Bio-Rad to Report Second Quarter 2022 Financial Results on Thursday, July 28, 2022
From Bio-Rad Laboratories, Inc.
Via Business Wire
This Healthcare Stock Jumped 110%; Here Are 64 Biggest Movers From Yesterday
 Gainers Virax Biolabs Group Limited (NASDAQ: VRAX) shares climbed 264% to close at $18.20 on Thursday. The company offered shares at an expected price of $5.00 per share with an insider lock-up period... 
Via Benzinga
Jim Cramer Says This Stock Is 'Too Risky'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he likes Cadre Holdings Inc (NYSE: CDRE) as it "makes things, does stuff, sells at a profit, gives you money back." 
Via Benzinga
Why Is Super Micro Computer Higher By More Than 13%? 42 Stocks Moving In Thursday's Mid-Day Session
Gainers Virax Biolabs Group Limited (NASDAQ: VRAX) shares jumped 364.3% to $23.22. The company offered shares at an expected price of $5.00 per share with an insider lock-up period of 180 days ending... 
Via Benzinga
Bio-Rad Publishes Corporate Sustainability Report
From Bio-Rad Laboratories, Inc.
Via Business Wire
7 Profitable Places to Hide Your Money During a Bear Market
With an imminent bear market on the horizon, investors are searching for alternative investment paths for diversification. 
Via InvestorPlace
5 Value Stocks To Watch In The Healthcare Sector
What Defines a Value Stock? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E... 
Via Benzinga
Recap: Bio-Rad Laboratories Q1 Earnings
Bio-Rad Laboratories (NYSE:BIO) reported its Q1 earnings results on Thursday, April 28, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Bio-Rad Reports First-Quarter 2022 Financial Results
From Bio-Rad Laboratories, Inc.
Via Business Wire
Bio-Rad to Report First-Quarter Financial Results, Thursday, April 28, 2022
From Bio-Rad Laboratories, Inc.
Via Business Wire
Will Investment Gains For Google Parent Reverse In Upcoming Earnings Report?
Investment gains have played a big role in earnings beats for GOOGL stock in recent years but that may reverse in its first-quarter earnings. 
Via Investor's Business Daily
Overview Of Value Stocks In The Healthcare Sector
What are Value Stocks? A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be... 
Via Benzinga
Upcoming Stock Splits 2022: 20 Companies That Could Follow Amazon’s Lead
We're taking a gander at more companies that could follow Amazon's (AMZN) lead with potential upcoming stock splits in 2022. 
Via InvestorPlace
Bio-Rad Presents Growth Strategy and Acceleration of Financial Targets at Investor Day
From Bio-Rad Laboratories, Inc.
Via Business Wire
7 Stocks To Buy at the Bottom After the Market Rout
The recent market rout offers an opportune entry point to these seven robust stocks. These are good stocks to buy at their bottom now. 
Via InvestorPlace
The Daily Biotech Pulse: Adcom Recommends Additional Trials For Lilly's Partnered Cancer Drug, Novavax Touts Pediatric Vaccine Data, TC Biopharm IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adcom Rules That Lilly May Have To Conduct Additional Studies For Co-... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.